Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
16 June 2021Website:
http://www.molecularpartners.comNext earnings report:
26 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:53:03 GMTDividend
Analysts recommendations
Institutional Ownership
MOLN Latest News
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners' leadership team will participate in upcoming investor events in Switzerland during January 2024. Conference Presentation Details
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present on several of its programs at the 15th Annual Protein & Antibody Engineering European Summit (PEGS Europe), which runs November 14-16 in Lisbon, Portugal. The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions. This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present preliminary data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 9–12 in San Diego, California. MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).
RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will present on its Radio DARPin Therapy (RDT) Platform at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held from June 24-27 in Chicago, Illinois.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 12:00 p.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Daniel Steiner, SVP Research.
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Patrick Amstuts, Chief Executive Officer, will participate in the 2023 RBC Capital Markets Global Healthcare Conference, in-person, May 16-17, 2023.
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that further preclinical data supporting the company's Radio DARPin Therapy Platform will be shared at the American Association for Cancer Research Annual Meeting held April 14-19 in Orlando, Florida.
What type of business is Molecular Partners AG?
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
What sector is Molecular Partners AG in?
Molecular Partners AG is in the Healthcare sector
What industry is Molecular Partners AG in?
Molecular Partners AG is in the Biotechnology industry
What country is Molecular Partners AG from?
Molecular Partners AG is headquartered in Switzerland
When did Molecular Partners AG go public?
Molecular Partners AG initial public offering (IPO) was on 16 June 2021
What is Molecular Partners AG website?
https://www.molecularpartners.com
Is Molecular Partners AG in the S&P 500?
No, Molecular Partners AG is not included in the S&P 500 index
Is Molecular Partners AG in the NASDAQ 100?
No, Molecular Partners AG is not included in the NASDAQ 100 index
Is Molecular Partners AG in the Dow Jones?
No, Molecular Partners AG is not included in the Dow Jones index
When does Molecular Partners AG report earnings?
The next expected earnings date for Molecular Partners AG is 26 August 2024